News Lilly’s Taltz scrapes win against Humira in psoriatic arthri... Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just.
News Amid tough competition, Novartis makes case for rheumatology... Swiss pharma hopes to bounce back from Q1 sales disappointment
News Novartis tests Cosentyx against Humira and biosimilars Trials will cover psoriatic arthritis and ankylosing spondylitis
News Pfizer's Xeljanz approved in psoriatic arthritis Xeljanz is first JAK inhibitor approved in psoriatic arthritis
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
